莫西沙星三联疗法在巴基斯坦幽门螺杆菌感染一线治疗中的疗效:随机对照试验

Sumaira Khadim, Iyad Naeem, Muhammad Alam, Hina Rehman, Sidra Ghayas, Sajjad Haider
{"title":"莫西沙星三联疗法在巴基斯坦幽门螺杆菌感染一线治疗中的疗效:随机对照试验","authors":"Sumaira Khadim, Iyad Naeem, Muhammad Alam, Hina Rehman, Sidra Ghayas, Sajjad Haider","doi":"10.5114/amscd.2023.131926","DOIUrl":null,"url":null,"abstract":"Introduction The challenge of eradicating <i>Helicobacter pylori</i> through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment. Material and methods A total of 162 patients who were examined positive for <i>H. pylori</i> were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days. Results The eradication rate of <i>H. pylori</i> in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group. Conclusions Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for <i>H. pylori</i> infection in Pakistan.","PeriodicalId":8317,"journal":{"name":"Archives of Medical Sciences. Atherosclerotic Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials\",\"authors\":\"Sumaira Khadim, Iyad Naeem, Muhammad Alam, Hina Rehman, Sidra Ghayas, Sajjad Haider\",\"doi\":\"10.5114/amscd.2023.131926\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction The challenge of eradicating <i>Helicobacter pylori</i> through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment. Material and methods A total of 162 patients who were examined positive for <i>H. pylori</i> were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days. Results The eradication rate of <i>H. pylori</i> in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group. Conclusions Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for <i>H. pylori</i> infection in Pakistan.\",\"PeriodicalId\":8317,\"journal\":{\"name\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Sciences. Atherosclerotic Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/amscd.2023.131926\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Sciences. Atherosclerotic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/amscd.2023.131926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

根除幽门螺杆菌的挑战<i>由于抗生素耐药性的存在,通过抗生素治疗仍然是一个值得关注的问题。本研究旨在评价和比较左氧氟沙星序贯治疗与莫西沙星三联治疗对接受一线治疗的幽门螺杆菌感染患者的疗效。材料与方法:对162例经检查为<i>H阳性的患者进行分析。pylori< / i>随机分为两组接受以下治疗:(a)前5天左氧氟沙星500mg BID、阿莫西林1g BID、奥美拉唑20mg BID,随后左氧氟沙星500mg BID、替硝唑500mg BID、奥美拉唑20mg BID (LAO-LTO组);结果:1种病原菌的根治率为100%;pylori< / i>莫西沙星三联疗法的根除率显著高于左氧氟沙星方案(p <0.001)。莫西沙星组总体不良反应发生率和患者依从性显著降低(p <0.005)高于左氧氟沙星组。结论与左旋氧氟沙星序贯治疗相比,莫西沙星三联疗法可显著提高根治H的一线疗效。pylori< / i>巴基斯坦的感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials
Introduction The challenge of eradicating Helicobacter pylori through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment. Material and methods A total of 162 patients who were examined positive for H. pylori were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days. Results The eradication rate of H. pylori in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group. Conclusions Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for H. pylori infection in Pakistan.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信